Led by figures from Oxford, Genomics England and the NHS, Aneira aims to tackle delays, data gaps and diagnostic bias in female healthcare.
When female-specific symptoms are filtered through diagnostic systems designed around the male body, it is perhaps unsurprising that outcomes fall short. With conditions such as endometriosis taking a decade to diagnose on average – and women still 50% more likely to experience adverse drug reactions due to underrepresentation in clinical research – the case for rethinking how healthcare is delivered to women has become increasingly urgent. The latest intervention in this space is Aneira Health: a new precision medicine platform founded by senior figures from Genomics England, Oxford University and the NHS, which launches with a stated ambition to rebuild care pathways from the biology up.
With the support of the Care Quality Commission and a clinical partnership with Guy’s and St Thomas’ NHS Trust already in place, Aneira brings together AI-enabled diagnostics, genomics, biomarker testing and a lifecycle model of care. The focus is unapologetically specific: addressing systemic failings in women’s health that contribute not only to personal suffering and lost quality of life, but to an estimated £11 billion in annual economic losses in the UK alone. Positioning itself between traditional health services and tech-enabled consumer care, Aneira is aiming for something more integrated – and more enduring – than a symptom-tracker or single-point solution.
Longevity.Technology: A £11 billion annual cost to the UK economy is a headline-grabbing statistic, but it’s only part of a much deeper global story – the underdiagnosis, undertreatment and underrepresentation of women in medical science. That’s not just a healthcare failure; it’s a longevity crisis. Healthspan equity begins with recognising biological differences, not designing around them – and Aneira’s arrival marks a significant course correction. By embedding genomics, AI and personalised diagnostics into a lifecycle care model, this new platform tackles issues that have long delayed or derailed women’s access to effective interventions.
What’s compelling here isn’t just the tech stack – it’s the shift in clinical architecture: building from the biology up, not retrofitting male-default systems. If longevity science is serious about inclusivity, Aneira may be a template worth watching – not just for women’s health, but for how we rethink precision care at scale. We sat down with Dr Nikita Kanani MBE, Chief Strategy and Innovation Officer at Aneira, to find out more.
Kanani explains that Aneira’s approach to female healthspan is shaped by a recognition that menopause and ovarian aging are not endpoints, but indicators. “We see menopause and ovarian aging not as isolated events, but as part of a much broader physiological shift that intersects with everything from cardiovascular risk to mental health and metabolic function,” she says. “We’re building a model that supports women before, during and long after menopause – not just to manage symptoms, but to optimize healthspan in a way that reflects women’s actual lives, needs and risks.”
Designing for difference, not default
That proactive stance is central to the platform’s use of early-stage biomarkers and AI-enabled risk prediction tools. “Ovarian aging isn’t just a reproductive milestone – it’s a signal,” says Kanani. “One that should prompt earlier, smarter interventions around bone density, heart health, brain aging and more. If we catch those inflection points early, we can make choices that genuinely alter the trajectory of a woman’s later-life health.”
Aneira also positions itself as a corrective to the historic absence of women in clinical research – an imbalance that continues to distort diagnostics and treatment efficacy. “This is one of the biggest systemic failures in medicine – and one we’re determined to address,” Kanani says. “At Aneira, we’re collecting data that reflects the actual diversity of women’s lives and bodies. That means disaggregating by sex, but also by ethnicity, age, hormonal status and lived experience. Precision medicine only works if the dataset is precise – and representative. We need to stop retrofitting women into models that were never built with them in mind.”
From one-off encounters to real-world, real-time care
The company’s commitment to real-world evidence extends to long-term data capture across its patient base. “Longitudinal data is a cornerstone of what we’re building,” she notes. Unlike fragmented or episodic health records, Aneira’s systems are designed to follow patients over time – capturing trends that could inform both individual care and wider population health insights. “We see an opportunity to become one of the most comprehensive sources of real-world, female-specific healthspan data in the UK. That kind of dataset doesn’t just improve individual outcomes – it can shift public health strategy, research priorities, even policy frameworks.”
Although Aneira begins with reproductive health, its remit goes well beyond. “We often say at Aneira that we start with reproductive health, but we don’t stop there,” says Kanani. “Post-menopause, the risks around cardiovascular disease, osteoporosis, dementia and type 2 diabetes all rise – and too often, those changes go unmonitored and untreated. We’re changing that. Our care model is built around the whole body – and the whole story.”
That includes a wide view of risk factors. “We look at biomarkers, health behaviours, family history, mental load and more,” she explains. “Then we design personalised plans that help delay, detect or disrupt decline. Whether that’s through hormone management, lifestyle intervention, screening or referrals, the goal is to support informed, proactive care throughout a woman’s life.”
Technology, in this context, is not just about automation or efficiency – it’s about making invisible trends visible, and acting on them with clarity and speed. “At Aneira, we’re using advanced diagnostics and AI tools to spot changes early – often before symptoms emerge,” says Kanani. “That might be subtle changes in hormone levels, metabolic markers or reported symptoms that signal increased risk. Because women’s symptoms are too often dismissed, we’re flipping that narrative: listening more closely, using technology to validate what’s happening, and acting faster.”
Equally, she emphasizes accessibility. “We’re also working to make these insights accessible – not hidden in complex reports, but shared in ways that women understand and can act on,” she adds. “It’s not just about adding tech – it’s about applying it in a way that respects women’s intelligence, bodies and time.”
As Kanani puts it: “We aim to equip women with what they need to age with strength – not just survive the transition.”
Article photographs courtesy of Aneira Health
The post Aneira Health launches precision platform for women’s healthspan appeared first on Longevity.Technology – Latest News, Opinions, Analysis and Research.
